There are 2789 resources available
1203P - The analysis of ALK fusion variants in 4991 EGFR/MET mutation-negative non-squamous non-small cell lung carcinomas (NSCLCs)
Presenter: Evgeny Imyanitov
Session: ePoster Display
1204P - Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Presenter: Ana Laura Ortega Granados
Session: ePoster Display
1178P - Senescence signature affects overall survival in non-small cell lung cancer
Presenter: Andreas Domen
Session: ePoster Display
1179P - The effect of neoadjuvant chemotherapy / chemoradiotherapy on tumor tissue PD-L1 and VISTA expression levels in non-small cell lung cancers (NSCLC)
Presenter: Orhun Akdogan
Session: ePoster Display
1180P - Anlotinib combined with radiotherapy in locally advanced non-small cell lung cancer (LANSCLC): A prospective, single-arm, phase II study
Presenter: Peng Ning
Session: ePoster Display
1209P - RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome
Presenter: Makoto Nishio
Session: ePoster Display
1210P - Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
Presenter: Baohui Han
Session: ePoster Display
1092TiP - Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
Presenter: Reinhard Dummer
Session: ePoster Display
1093TiP - An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Presenter: Francesca Aroldi
Session: ePoster Display